Developing differentiated medicines

for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases

Exploring the Brain Immune Gut (BIG) Axis

23 product candidates

14 are clinical stage

1 FDA cleared product

Relationships with 8 major pharma companies
or their investment arms

 

Team of industry leaders and experts

Publications
Publications -2018-03-23
Internal Pipeline
PureTech's Lymphatic Leap
Publications -2017-09-19
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Publications -2017-09-19
Vedanta
Science: The Gut’s Clostridium Cocktail
Press releases
2020-03-11
PureTech Affiliate Gelesis Named One of the World’s Most Innovative Companies for 2020 by Fast Company

Continue

Press releases
2020-03-10
Notice of Results

 

Continue

Press releases
2020-03-03
PureTech Announces First Participant Dosed in Clinical Trial of Wholly-Owned Lymphoedema Candidate LYT-100

Continue